The technology allows for a single in-office minimally invasive surgical procedure. The patent also allows the device to deliver medication or therapeutic agents to the uterine cavity.

ContraMed has also received a notice of allowance for US patent application 11/884,027 I intrauterine fallopian tube occlusion device and method for use which covers an occlusion device for actively occluding the orifices of the fallopian tubes using the shape of the uterine cavity as a guide.

Beyond the newly announced intellectual property, ContraMed has tested its devices with impressive pilot clinical study results.

Michael Sinsheimer, president of ContraMed, said: “Today’s announcement broadens our current expansive patent portfolio covering a unique device that can be used as a tubal occlusion product and/or an intra-uterine device (IUD). Our technology is designed to be less invasive than the other available tubal occlusion products and to be non hormonal and not be made of copper from an IUD perspective.”

Steven Goldstein, professor of obstetrics and gynecology at New York University Langone Medical Center, said: “The ContraMed device will revolutionize contraception by making it less invasive and more women friendly. It will provide non-hormonal contraception which eliminates the risk of hormonal side effects. Initial clinical studies show great promise.”

ContraMed is an early-stage company that was founded to develop contraceptive devices which are intended to change the paradigm of sterilisation and intra-uterine devices by being minimally invasive and inserted on an outpatient basis.